By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel unanimously agrees that the article is misinformation, fabricating a SpaceX IPO on June 12 at a $1.8T valuation. They caution against investing in high-fee funds like ARKVX or XOVR, which provide illiquid exposure to SpaceX and may never convert to public equity.
Risk: Investing in high-fee funds for illiquid exposure to a company that may never go public
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The SpaceX IPO could break records.
There are a few ways to buy in before shares go public.
It's official: SpaceX is planning an initial public offering (IPO) on June 12 that will likely push the company's valuation to $1.8 trillion when shares begin trading on the Nasdaq exchange under the ticker symbol SPCX.
According to reports, the company plans to sell 555.6 million shares at $135 apiece, raising around $75 billion in new capital. Underwriters have the option to purchase an additional 83.33 million shares at the IPO price, which would contribute an additional $11.2 billion in new capital. Of course, underwriters will likely only exercise this option if the trading price exceeds the IPO sale price. With IPO stocks often showing high initial volatility, anything is possible.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
But you don't need to wait for the IPO to get exposure to SpaceX stock. There are two ways in particular to get SpaceX exposure today.
According to reports, SpaceX founder and CEO Elon Musk currently owns around 85% of SpaceX's shares. Employees and various venture capital investors own the rest. The company already has an internal trading program that allows employees and existing investors to sell shares, but this program isn't available to outside investors.
How, then, can you buy SpaceX stock today? There are a few ways to accomplish this, but most require high fees or restrictions. By far the easiest method is to simply buy into an investment vehicle like the ARK Venture Fund (NASDAQMUTFUND: ARKVX) or the ERShares Private-Public Crossover ETF (NASDAQ: XOVR).
Neither the ARK Venture Fund nor the ERShares Private-Public Crossover ETF is perfect. The former has just 11% of its portfolio invested in SpaceX stock, whereas the latter has roughly 20% exposure. That means that buying these ETFs dilutes your ultimate SpaceX exposure by around 80% to 90%.
Plus, both of these investment vehicles also come with high costs. The ARK Venture fund has an expense ratio of roughly 3%, while the ERShares Private-Public Crossover ETF charges around 0.75% -- both of which are higher than fees for broad market index fund ETFs.
Most investors are simply better off waiting for the company's official IPO to buy shares. In fact, some experts believe that buying shares after the IPO might be the best approach.
"[L]ong-term investors eager to participate in SpaceX's future endeavors and potential success will have opportunities to do so with a greater margin of safety than the initial offering is likely to provide," recommends an analyst from Morningstar. "We think the company has been significantly overvalued and investors will have opportunities to buy the stock at more attractive levels after the IPO."
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 960%* — a market-crushing outperformance compared to 211% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
**Stock Advisor returns as of June 4, 2026. *
Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The article’s implied $1.8 trillion valuation is highly unlikely given available private-market signals and would likely unwind sharply after formal disclosures."
The strongest case against the obvious reading is that the article’s numbers don’t pass sniff tests. SpaceX’s private-market valuations have been in the low hundreds of billions, not $1.8 trillion, and there is no vetted public filing confirming SPCX or the June 12 timing. If an IPO happens, value would hinge on fundamentals (revenue, cash flow, leverage, government/defense demand) and on governance risks from Elon Musk’s ~85% stake, which could limit upside for public investors. The implied capital raise ($75B) and the post-money optics clash with typical IPO math; mispricing risk looms, and the market would likely re-rate aggressively after any official disclosure.
Even if SpaceX goes public, the article’s valuation and deal size seem implausible—market reality would push the price down toward more conservative levels once real disclosures appear.
"The reported SpaceX IPO date and ticker are factually incorrect and appear to be fabricated, rendering the entire investment premise of the article fraudulent."
This article is a classic example of financial misinformation. As of mid-2024, there is no official SEC filing, no confirmed June 12 IPO date, and no 'SPCX' ticker for SpaceX. The company remains private, and Elon Musk has repeatedly indicated no immediate plans for a public offering of the parent company, potentially spinning off Starlink instead. Investors chasing this 'opportunity' via high-fee funds like ARKVX or XOVR are buying into secondary market proxies at a significant premium to NAV (Net Asset Value), essentially paying a high management fee for exposure that may never materialize as a direct equity stake in the core launch business.
If SpaceX were to suddenly pivot to an IPO to fund aggressive Mars colonization, the valuation could theoretically justify a premium, but the lack of verifiable regulatory filings makes this current report entirely speculative.
"This article invents a SpaceX IPO as pretext to market high-fee funds; the fabricated details (June 12, $1.8T, SPCX ticker) have zero public confirmation and should disqualify it as investment guidance."
This article is a marketing piece masquerading as news—it fabricates a specific IPO date (June 12), valuation ($1.8T), share count, and ticker (SPCX) with no credible sourcing. SpaceX has never announced an IPO. The article then pivots to selling readers on existing funds (ARKVX, XOVR) by claiming they're the only pre-IPO path, despite acknowledging 80–90% dilution and 0.75–3% fees. Even Morningstar's quoted skepticism gets buried. This is a bait-and-switch: create urgency around a fictional event, then funnel readers into high-fee vehicles. The real story—if SpaceX *ever* goes public—would depend on profitability, regulatory risk (national security concerns around Starlink), and whether Musk's 85% stake creates governance red flags.
If SpaceX does eventually IPO, the article's core point holds: waiting for the actual offering beats overpaying through intermediaries. And if you believe SpaceX's long-term dominance in launch and satellite internet is real, even 11–20% exposure through ARKVX beats zero exposure today.
"No credible evidence supports an imminent SpaceX IPO, so allocating to ARKVX for 11% diluted exposure is a high-fee gamble on fabricated news."
The article's core premise—that SpaceX will IPO on June 12 at a $1.8T valuation under ticker SPCX—is unsupported by any verifiable announcement from the company or regulators. SpaceX remains private with no disclosed plans for a public listing, rendering the touted exposure vehicles (ARKVX at 11% allocation and XOVR at 20%) speculative bets on nonexistent liquidity events. High fees compound the issue: ARKVX's ~3% expense ratio erodes returns even if SpaceX shares were accessible. Investors chasing pre-IPO hype risk capital locked in illiquid, overvalued private holdings that may never convert to public equity. The Morningstar quote on post-IPO buying is moot without an actual offering.
If SpaceX quietly files confidentially under new SEC rules, early vehicles like ARKVX could capture a sudden re-rating before retail access, making the wait-and-see stance miss a narrow window.
"Pre-IPO hype risks misallocating capital into illiquid proxies with high fees, which may never convert into public equity even if a legitimate offering later materializes."
Claude's bait-and-switch critique overlooks a real risk: even without a June 12 IPO, the hype can distort capital allocation in pre-IPO proxies. If credible filings do emerge later, the market could reprice SpaceX aggressively, but that requires execution risk on governance, financing appetite, and national security/regulatory approval—not just a marketing piece. For readers, the bigger danger is paying 2-4% fees for illiquid exposure that may never convert to public equity.
"High-fee pre-IPO funds create artificial demand that distorts price discovery and traps retail capital in illiquid assets."
Claude correctly identifies the marketing ploy, but we must address the systemic risk of 'synthetic' exposure. By funneling retail capital into high-fee funds like ARKVX based on phantom IPO dates, these vehicles create artificial demand for illiquid private shares. This drives up NAVs, benefiting early fund insiders while leaving late-stage retail investors holding the bag if the IPO never materializes. It is not just a bait-and-switch; it is a distortion of price discovery in the private markets.
"The fee drag and illiquidity risk are immediate and real; the IPO hype is secondary noise."
Gemini's 'synthetic demand' critique is sharp, but it conflates two separate risks. High-fee funds distorting NAVs is real—but that's a fund governance problem, not proof the IPO hype itself is fabricated. Claude and Grok are right that the June 12 date is invented. But ChatGPT's point stands: even without an IPO, capital misallocation into ARKVX happens *today*, regardless of future regulatory filings. The real victim isn't 'late retail'—it's anyone paying 3% annually for illiquid exposure to a company that may never go public.
"Fund-driven private valuation inflation risks anchoring any future IPO price unrealistically high."
Gemini's synthetic-demand point links directly to ChatGPT's allocation risk but misses the feedback loop: inflated private valuations from ARKVX/XOVR buying could anchor SpaceX's eventual IPO price too high, raising execution risk on any real filing. That same loop also heightens governance friction once Musk's stake faces public scrutiny, an angle none of the prior takes quantified against the 85% ownership.
The panel unanimously agrees that the article is misinformation, fabricating a SpaceX IPO on June 12 at a $1.8T valuation. They caution against investing in high-fee funds like ARKVX or XOVR, which provide illiquid exposure to SpaceX and may never convert to public equity.
None identified
Investing in high-fee funds for illiquid exposure to a company that may never go public